文献速递间质性肺疾病肺结节与肺癌

SFTPA1与SFTPA2突变在间质性肺疾病和肺癌中的功能评估与表型异质性

Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer.
PubMed 文献 · Eur Respir J · 2020-12-24

研究对14例独立患者的11种SFTPA1或SFTPA2突变进行功能评估,发现突变蛋白生成保留但分泌受阻,肺组织SP-A表达改变;14个家族中13个(93%)有ILD和/或肺腺癌家族史,28名携带者ILD平均发病年龄45岁,48%接受肺移植。

要点

  • SFTPA1/SFTPA2致病突变导致SP-A蛋白分泌受阻而生成保留。
  • 携带者ILD平均发病年龄45岁,48%接受肺移植,表型异质性大。
  • 14个家族中13个(93%)报告ILD和/或肺腺癌家族史。

核心结论

  • 致病性SFTPA1或SFTPA2突变在细胞模型和肺组织免疫染色中均导致SP-A分泌受阻,但疾病表型高度可变,从需肺移植的严重形式到不完全外显。

研究设计与样本

  • 在ILD分子诊断框架下识别14例独立携带SFTPA1或SFTPA2突变的患者,对11种不同突变进行体外蛋白生成与分泌研究及肺组织SP-A表达分析,并记录相关疾病表型。

主要发现

  • 11种突变均表现为蛋白生成保留但分泌丧失。
  • 6例患者肺组织SP-A表达模式发生改变。
  • 14个家族中13个(93%)报告ILD和/或肺腺癌家族史。
  • 28名SFTPA1或SFTPA2突变携带者中,ILD平均发病年龄45岁(范围0.6-65岁),48%接受肺移植(平均年龄51岁)。
  • 7名携带者无症状。

关键数值与推荐

  • 11种SFTPA1或SFTPA2突变:蛋白生成保留、分泌丧失。
  • 14个家族中13个(93%)有ILD和/或肺腺癌家族史。
  • 28名携带者:ILD平均发病年龄45岁(范围0.6-65岁),48%接受肺移植(平均年龄51岁),7名无症状。

临床怎么用

  • 对ILD患者进行SFTPA1/SFTPA2基因检测有助于分子诊断,并应关注ILD和肺腺癌家族史。
  • 携带者表型异质性大,需个体化随访,包括无症状携带者的监测。

局限性

  • 肺组织SP-A表达分析仅6例患者可用。
  • 样本量有限(14例独立患者、28名携带者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Interstitial lung diseases (ILDs) can be caused by mutations in the SFTPA1 and SFTPA2 genes, which encode the surfactant protein (SP) complex SP-A. Only 11 SFTPA1 or SFTPA2 mutations have so far been reported worldwide, of which five have been functionally assessed. In the framework of ILD molecular diagnosis, we identified 14 independent patients with pathogenic SFTPA1 or SFTPA2 mutations. The present study aimed to functionally assess the 11 different mutations identified and to accurately describe the disease phenotype of the patients and their affected relatives. METHODS: The consequences of the 11 SFTPA1 or SFTPA2 mutations were analysed both in vitro, by studying the production and secretion of the corresponding mutated proteins and ex vivo, by analysing SP-A expression in lung tissue samples. The associated disease phenotypes were documented. RESULTS: For the 11 identified mutations, protein production was preserved but secretion was abolished. The expression pattern of lung SP-A available in six patients was altered and the family history reported ILD and/or lung adenocarcinoma in 13 out of 14 families (93%). Among the 28 SFTPA1 or SFTPA2 mutation carriers, the mean age at ILD onset was 45 years (range 0.6-65 years) and 48% underwent lung transplantation (mean age 51 years). Seven carriers were asymptomatic. DISCUSSION: This study, which expands the molecular and clinical spectrum of SP-A disorders, shows that pathogenic SFTPA1 or SFTPA2 mutations share similar consequences for SP-A secretion in cell models and in lung tissue immunostaining, whereas they are associated with a highly variable phenotypic expression of disease, ranging from severe forms requiring lung transplantation to incomplete penetrance.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Legendre M, Butt A, Borie R, et al. Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer. Eur Respir J. 2020. PMID: 32855221. doi:10.1183/13993003.02806-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。